Last reviewed · How we verify

Standard-vaginal misoprostol

Antonios Likourezos · FDA-approved active Small molecule Quality 5/100

Standard-vaginal misoprostol is a Small molecule drug developed by Antonios Likourezos. It is currently FDA-approved. Also known as: perivascular vasopresssin-vaginal misprostol.

At a glance

Generic nameStandard-vaginal misoprostol
Also known asperivascular vasopresssin-vaginal misprostol
SponsorAntonios Likourezos
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Standard-vaginal misoprostol

What is Standard-vaginal misoprostol?

Standard-vaginal misoprostol is a Small molecule drug developed by Antonios Likourezos.

Who makes Standard-vaginal misoprostol?

Standard-vaginal misoprostol is developed and marketed by Antonios Likourezos (see full Antonios Likourezos pipeline at /company/antonios-likourezos).

Is Standard-vaginal misoprostol also known as anything else?

Standard-vaginal misoprostol is also known as perivascular vasopresssin-vaginal misprostol.

What development phase is Standard-vaginal misoprostol in?

Standard-vaginal misoprostol is FDA-approved (marketed).

Related